ID: ALA4438759

Max Phase: Preclinical

Molecular Formula: C26H31N3O5

Molecular Weight: 465.55

Molecule Type: Unknown

Representations

Canonical SMILES:  CCCOc1ccc(NC(=O)CCCOc2cc3c(cc2OC)C(=O)N2CCC[C@H]2C=N3)cc1

Standard InChI:  InChI=1S/C26H31N3O5/c1-3-13-33-20-10-8-18(9-11-20)28-25(30)7-5-14-34-24-16-22-21(15-23(24)32-2)26(31)29-12-4-6-19(29)17-27-22/h8-11,15-17,19H,3-7,12-14H2,1-2H3,(H,28,30)/t19-/m0/s1

Standard InChI Key:  XNPZTMNHZWWXDJ-IBGZPJMESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 465.55

Molecular Weight (Monoisotopic): 465.2264

AlogP: 4.60

#Rotatable Bonds: 10

Polar Surface Area: 89.46

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 4.06

CX LogP: 3.24

CX LogD: 3.24

Aromatic Rings: 2

Heavy Atoms: 34

QED Weighted: 0.52

Np Likeness Score: -0.54

References

1. Corcoran DB, Lewis T, Nahar KS, Jamshidi S, Fegan C, Pepper C, Thurston DE, Rahman KM..  (2019)  Effects of Systematic Shortening of Noncovalent C8 Side Chain on the Cytotoxicity and NF-κB Inhibitory Capacity of Pyrrolobenzodiazepines (PBDs).,  62  (4): [PMID:30688457] [10.1021/acs.jmedchem.8b01849]

Source

Source(1):

• Scientific Literature